デフォルト表紙
市場調査レポート
商品コード
966799

多発性骨髄腫関連骨疾患:疫学的考察 (2030年まで)

Multiple myeloma-related bone disease - Epidemiology Insight - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円
多発性骨髄腫関連骨疾患:疫学的考察 (2030年まで)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の主要国 - 米国、欧州主要5ヶ国 (EU5:フランス・ドイツ・イタリア・スペイン・英国) 、日本 - における多発性骨髄腫関連の骨疾患の疫学的動向と今後の見通し (過去3年間・今後11年間分) について分析しております。

目次

第1章 主な考察

第2章 多発性骨髄腫関連骨疾患:エグゼクティブサマリー

第3章 多発性骨髄腫関連骨疾患:疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理
  • 危険因子
  • 診断方法

第4章 ペイシェント・ジャーニー

第5章 疫学と患者人口

  • 疫学分析のポイント
  • 仮定と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 多発性骨髄腫関連骨疾患:主要7ヶ国における疫学シナリオ (2017年~2030年)
  • 米国の疫学的動向
    • 米国国内の多発性骨髄腫関連骨疾患の疫学シナリオ (2017年~2030年)
  • 欧州5ヶ国:国別の疫学的動向
    • ドイツの疫学的動向
    • フランスの疫学的動向
    • イタリアの疫学的動向
    • スペインの疫学的動向
    • 英国の疫学的動向
  • 日本の疫学的動向
    • 日本国内の多発性骨髄腫関連骨疾患の疫学シナリオ (2017年~2030年)

第6章 治療アルゴリズム、現在の治療・診療方法

  • 多発性骨髄腫関連骨疾患の治療・管理方法
  • 多発性骨髄腫関連骨疾患の治療アルゴリズム

第7章 業界の有識者 (KOL) の見解

第8章 アンメットニーズ

第9章 付録

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Multiple myeloma-related bone disease Epidemiology in 7MM (2017-2030)
  • Table 2: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Multiple myeloma-related bone disease Epidemiology in the United States (2017-2030)
  • Table 4: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Multiple myeloma-related bone disease Epidemiology in Germany (2017-2030)
  • Table 6: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Multiple myeloma-related bone disease Epidemiology in France (2017-2030)
  • Table 8: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Multiple myeloma-related bone disease Epidemiology in Italy (2017-2030)
  • Table 10: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Multiple myeloma-related bone disease Epidemiology in Spain (2017-2030)
  • Table 12: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Multiple myeloma-related bone disease Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Multiple myeloma-related bone disease Epidemiology in Japan (2017-2030)
  • Table 16: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Multiple myeloma-related bone disease Epidemiology in 7MM (2017-2030)
  • Figure 2: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Multiple myeloma-related bone disease Epidemiology in the United States (2017-2030)
  • Figure 4: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Multiple myeloma-related bone disease Epidemiology in Germany (2017-2030)
  • Figure 6: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Multiple myeloma-related bone disease Epidemiology in France (2017-2030)
  • Figure 8: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Multiple myeloma-related bone disease Epidemiology in Italy (2017-2030)
  • Figure 10: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Multiple myeloma-related bone disease Epidemiology in Spain (2017-2030)
  • Figure 12: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Multiple myeloma-related bone disease Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Multiple myeloma-related bone disease Epidemiology in Japan (2017-2030)
  • Figure 16: Multiple myeloma-related bone disease Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1074

DelveInsight's 'Multiple myeloma-related bone disease - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Multiple myeloma-related bone disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Multiple myeloma-related bone disease Understanding

The DelveInsight Multiple myeloma-related bone disease epidemiology report gives a thorough understanding of the Multiple myeloma-related bone disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Multiple myeloma-related bone disease in the US, Europe, and Japan. The report covers the detailed information of the Multiple myeloma-related bone disease epidemiology scenario in seven major countries (US, EU5, and Japan).

Multiple myeloma-related bone disease Epidemiology Perspective by DelveInsight

The Multiple myeloma-related bone disease epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Multiple myeloma-related bone disease epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Multiple myeloma-related bone disease epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Multiple myeloma-related bone disease Detailed Epidemiology Segmentation

The Multiple myeloma-related bone disease epidemiology covered in the report provides historical as well as forecasted Multiple myeloma-related bone disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Multiple myeloma-related bone disease report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Multiple myeloma-related bone disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Multiple myeloma-related bone disease Epidemiology Report and Model provide an overview of the risk factors and global trends of Multiple myeloma-related bone disease in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Multiple myeloma-related bone disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Multiple myeloma-related bone disease
  • The report provides the segmentation of the Multiple myeloma-related bone disease epidemiology

Report Highlights:

  • 11-Year Forecast of Multiple myeloma-related bone disease epidemiology
  • 7MM Coverage
  • Total Cases of Multiple myeloma-related bone disease
  • Total Cases of Multiple myeloma-related bone disease according to segmentation
  • Diagnosed cases of Multiple myeloma-related bone disease

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Multiple myeloma-related bone disease ?
  • What are the key findings pertaining to the Multiple myeloma-related bone disease epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Multiple myeloma-related bone disease across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Multiple myeloma-related bone disease ?
  • What are the currently available treatments of Multiple myeloma-related bone disease ?

Reasons to buy:

  • The Multiple myeloma-related bone disease Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Multiple myeloma-related bone disease market
  • Quantify patient populations in the global Multiple myeloma-related bone disease market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Multiple myeloma-related bone disease therapeutics in each of the markets covered
  • Understand the magnitude of Multiple myeloma-related bone disease population by its epidemiology
  • The Multiple myeloma-related bone disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Multiple myeloma-related bone disease

3. Multiple myeloma-related bone disease : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Multiple myeloma-related bone disease Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Multiple myeloma-related bone disease Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Multiple myeloma-related bone disease Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Multiple myeloma-related bone disease Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Multiple myeloma-related bone disease Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Multiple myeloma-related bone disease Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Multiple myeloma-related bone disease Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Multiple myeloma-related bone disease Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Multiple myeloma-related bone disease Treatment and Management
  • 6.2. Multiple myeloma-related bone disease Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report